We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+48.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$490M
Cap. Flow
-$84M
Cap. Flow %
-3.62%
Top 10 Hldgs %
54.22%
Holding
73
New
11
Increased
23
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$72.8M
2
AZN icon
AstraZeneca
AZN
+$70.9M
3
LLY icon
Eli Lilly
LLY
+$59M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$56.9M
5
ABBV icon
AbbVie
ABBV
+$38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$139M
2
BSX icon
Boston Scientific
BSX
+$55.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$53.2M
4
ROIV icon
Roivant Sciences
ROIV
+$47.6M
5
DXCM icon
DexCom
DXCM
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
51
Axsome Therapeutics
AXSM
$12.3B
$2.24M 0.1%
12,266
-381,233
-97% -$53.2M
ESTA icon
52
Establishment Labs
ESTA
$2.71B
$2.07M 0.09%
28,366
+17,579
+163% +$1.06M
RARE icon
53
Ultragenyx Pharmaceutical
RARE
$2.65B
$1.92M 0.08%
+83,300
New +$2.74M
SVRA icon
54
Savara
SVRA
$1.11B
$1.84M 0.08%
304,770
-2,122,954
-87% -$10.4M
MIRM icon
55
Mirum Pharmaceuticals
MIRM
$6.96B
$1.82M 0.08%
+23,100
New +$1.66M
ACAD icon
56
Acadia Pharmaceuticals
ACAD
$4.35B
$1.75M 0.08%
65,567
+38,767
+145% +$926K
JBIO
57
Jade Biosciences
JBIO
$1.21B
$1.66M 0.07%
107,391
– –
BOLT icon
58
Bolt Biotherapeutics
BOLT
$7.63M
$753K 0.03%
137,721
– –
SLNO
59
DELISTED
Soleno Therapeutics
SLNO
$575K 0.02%
12,414
-153,867
-93% -$8.44M
IMA
60
ImageneBio Inc
IMA
$63.2M
$220K 0.01%
31,884
– –
AKRO
61
DELISTED
Akero Therapeutics
AKRO
– –
-473,625
Closed -$22.5M
BSX icon
62
Boston Scientific
BSX
$67.6B
– –
-569,427
Closed -$55.6M
GILD icon
63
Gilead Sciences
GILD
$162B
– –
-1,252,312
Closed -$139M
IBB icon
64
PUT
iShares Biotechnology ETF
IBB
$9.44B
– –
-325,000
Closed -$46.9M
LQDA icon
65
PUT
Liquidia Corp
LQDA
$7.51B
– –
-250,000
Closed -$5.68M
MRUS
66
DELISTED
Merus
MRUS
– –
-166,729
Closed -$15.7M
PTCT icon
67
PTC Therapeutics
PTCT
$6.29B
– –
-186,932
Closed -$11.5M
QURE icon
68
CALL
uniQure
QURE
$2.63B
– –
-300,000
Closed -$17.5M
QURE icon
69
PUT
uniQure
QURE
$2.63B
– –
-500,000
Closed -$29.2M
SMMT icon
70
CALL
Summit Therapeutics
SMMT
$10.5B
– –
-900,000
Closed -$18.6M
SRRK icon
71
Scholar Rock
SRRK
$5.86B
– –
-31,410
Closed -$1.17M
UTHR icon
72
PUT
United Therapeutics
UTHR
$26.3B
– –
-97,100
Closed -$40.7M
XBI icon
73
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
– –
-400,000
Closed -$40.1M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2025 Portfolio in Review

As of Q4 2025, Sofinnova Investments held 73 positions worth $2.32B, up 27% from $1.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments withdrew a net $84M in Q4 2025, closing 13 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Bristol-Myers Squibb worth $81.6M.

  • Sofinnova Investments's largest Q4 2025 buy was Bristol-Myers Squibb: 1,512,994 shares worth $81.6M.
  • Sofinnova Investments added most to AstraZeneca in Q4 2025, an estimated $70.9M increase.
  • Sofinnova Investments's biggest Q4 2025 reduction was Axsome Therapeutics, cutting an estimated $53.2M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2025, selling an estimated $139M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $2.32B portfolio in Q4 2025.
  • Sofinnova Investments opened 11 new positions and closed 13 in Q4 2025.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $2.32B.

Based on Sofinnova Investments's 13F filing for Q4 2025, filed 13 Feb 2026.